NEW YORK (GenomeWeb News) - Illumina and ReaMetrix plan to develop molecular diagnostic panels for several diseases, the companies said today.

 
The panels will "help predict the risk of disease, enable earlier intervention, and guide therapy," Jay Flatley, Illumina president and CEO, said in a statement.
 
Terms of the agreement call for Illumina to supply its VeraCode technology and other reagents while ReaMetrix will develop, validate, and market the panels.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.